Galantamine (reminyl) in the treatment of severe Alzheimer’s disease

Authors

Gavrilova, S. I., Kolykhanov, I. V., Kalyn, Ia B., Selezneva, N. D.

Journal

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia I Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov [I] Vserossiĭskoe Obshchestvo Psikhiatrov, Volume: 109, No.: 7, Pages.: 57-61

Year of Publication

2009

Abstract

Twenty-five patients with Alzheimer’s disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the antipsychotic therapy. Reminyl had a positive effect on cognitive functions and psychotic symptoms of dementia, in particular delusions, aggression and irritability, apathy, aberrant motor behavior, eating and sleep disorders. The therapeutic reduction of these disorders resulted in the distinct reduction of physical and mental burden on the caregivers. The therapeutic effects of reminyl and its good tolerability allow to recommend this drug for treatment of severe stages of AD.;

Keywords

administration & dosage, aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, cognition, diagnosis, drug effects, drug therapy, female, galantamine, humans, male, middle aged, reminyl, severity of illness index, therapeutic use, treatment outcome

Types of Dementia

Alzheimer’s Disease

Types of Study

Case Control Study

Type of Outcomes

Behaviour, Carers’ Mental Health, Carers’ Physical Health, Cognition

Type of Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime, Antipsychotics and antidepressants